Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
Conditions: Carcinoma of Urinary Tract; Urethral Carcinoma; Carcinoma of Ureter; Carcinoma of Renal PelvisInterventions: Drug: Docetaxel; Biological: Ramucirumab DP; Biological: IMC-18F1Sponsor: Eli Lilly and CompanyActive, not recruiting - verified March 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Docetaxel | Research | Study | Taxotere | Urethral Cancer